يتناول هذا البروتوكول البالغين من عمر 18 عاماً فأكثر المصابين بعدوى التهاب الكبد C المزمن من أي نمط جيني، والذين لم يتلقوا علاجاً سابقاً لفيروس الكبد C — بما في ذلك الأشخاص المصابون بفيروس نقص المناعة البشري — ولا يعانون من تليف الكبد أو لديهم تليف كبد تعويضي فحسب.
DOI: 10.1093/cid/ciad319
Adults with chronic HCV infection, including persons living with HIV:
Have not previously received HCV treatment
Without cirrhosis or with compensated cirrhosis (Child-Pugh A) as determined by:
The HCV guidance first introduced the simplified treatment algorithms for treatment-naive persons (without cirrhosis or with compensated cirrhosis) in 2019.
Recommended DAA regimens for this simplified treatment approach include either 8 weeks of glecaprevir (300 mg)/pibrentasvir (120 mg) taken with food or 12 weeks of sofosbuvir (400 mg)/velpatasvir (100 mg).
For genotype 3 infection with compensated cirrhosis, NS5A RAS testing is recommended. If baseline NS5A RAS Y93H is present, add weight-based ribavirin or choose another recommended regimen.
Applicable to patients without cirrhosis who are not living with human immunodeficiency virus and whose HCV RNA is <6 million IU/mL.
SVR12, sustained virologic response 12 weeks after completion of therapy.
View source ↗